Publication | Closed Access

Optimizing Anti-TNF-α Therapy: Serum Levels of Infliximab and Adalimumab Are Associated With Mucosal Healing in Patients With Inflammatory Bowel Diseases

InflammationRheumatologyMucosal HealingAnti-inflammatoryAutoimmune DiseaseImmunologyGastroenterologyChronic InflammationPathologyAnti-tnf-α TherapyImmune-mediated Inflammatory DiseasesImmunotherapyMedicineInflammatory DiseaseSerum Levels